Table 1.
Published studies of targeted anti-neoplastic treatments utilizing novel patient-derived tumor xenografts models in renal cell carcinoma.
| Study Name | Cancer Type | PDX Tumor Models | Graft Location | PDX Line | Targets | Drugs/Therapies |
|---|---|---|---|---|---|---|
| Elbanna et al. (2019) [51] | Clear cell renal cell carcinoma | 3 | Orthotopic and subcutaneous heterotopic | RP-R-01, RP-R-02, and RP-R02LM | Angiopoietin 1/2, MET kinase | Trebananib (angiopoietin 1/2 inhibitor), MET kinase inhibitor |
| Schueler et al. (2018) [50] | Clear cell, papillary, chromophobe renal cell carcinoma | 44 | Subcutaneous heterotopic | Institutional: University Hospital Frankfurt | VEGF, VHL-associated targets, mTOR | Sunitinib, pazopanib, sorafenib, axitinib, temsirolimus, bevacizumab |
| Adelaiye-Ogala et al. (2018) [52] | Clear cell renal cell carcinoma | 2 | Subcutaneous heterotopic | RP-R-02LM, 786-O | Androgen receptor, receptor tyrosine kinase | Enzalutamide, sunitinib |
| Damayanti et al. (2018) [53] | Translocation renal cell carcinoma | 1 | Subcutaneous heterotopic | RP-R07 | PI3K/AKT/mTOR pathways | Rapamycin, MLN0128 (mTOR inhibitor), BEZ-235 (PI3K inhibitor) |
| Zhao et al. (2017) [54] | Papillary renal cell carcinoma | 1 | Orthotopic and subcutaneous heterotopic | Institutional tumor | MET | Cabozantinib |
| Adelaiye-Ogala et al. (2017) [55] | Clear cell renal cell carcinoma | 2 | Ectopic in prostate (metastatic model), Orthotopic, and Subcutaneous heterotopic | RP-R-01, RP-R-02, and RP-R02LM | EZH2, VEGF | HKT288, sunitinib, axitinib, bevacizumab |
| Bialucha et al. (2017) [56] | Clear cell renal cell Carcinoma | 3 | Subcutaneous heterotopic | Multiple institutional tumors, commercial vendors | CDH6 | HKT288 (anti-CDH6 antibody drug conjugate) |
| Dong et al. (2017) [57] | Renal cell Carcinoma | 33 | Subcutaneous heterotopic | Institutional: Memorial Sloan Kettering Cancer Center (New York) | Receptor tyrosine kinase | Sunitinib |
| Hong et al. (2017) [58] | Renal cell Carcinoma | 2 | Subcutaneous heterotopic | Institutional: Peking University Hospital (Peking) | PDGFA, PDGFB, PDGFRA | Sorafenib, sunitinib, axitinib |
| Chen et al. (2016) [59] | Renal cell carcinoma | 22 | Orthotopic | Institutional: UT Southwestern (Dallas, TX) | HIF-2 | PT2399 (HIF-2 antagonist), sunitinib |
| Diaz-Montero et al. (2016) [60] | Renal cell carcinoma | 2 | Subcutaneous heterotopic | Institutional: Cleveland Clinic (Cleveland, OH) | MEK1/2 | Sunitinib, PD-0325901 (MEK inhibitor) |
| Lang et al. (2016) [61] | Renal cell carcinoma | 30 | Orthotopic and Subcutaneous heterotopic | Institutional: Hôpitaux Universitaires de Strasbourg (France) | VHL-associated targets | Sunitinib, sorafenib, everolimus |
| Adelaiye et al. (2015) [62] | Clear cell renal cell carcinoma | 2 | Subcutaneous heterotopic | RP-R-01 and RP-R-02 | Receptor tyrosine kinase | Sunitinib |
| Ciamporcero et al. (2015) [63] | Renal cell carcinoma | 1 | Subcutaneous heterotopic | RP-R-01 | VEGF and HGF/c-met pathway | Axitinib, crizotinib, sunitinib |
| Schuller et al. (2015) [64] | Papillary renal cell carcinoma | 2 | Subcutaneous heterotopic | RCC-43b and RCC-47 PRCC | MET | Savolitinib, sunitinib |
| Miles et al. (2014) [65] | Clear cell renal cell carcinoma | 2 | Subcutaneous heterotopic | RP-R-01 and RP-R-02 | DII4, VEGF, | REGN (mAb binding DII4), ziv-aflibercept (VEGF blocker), sunitinib |
| Thong et al. (2014) [23] | Renal cell carcinoma | 13 | Orthotopic | Institutional: Stanford Hospital (Stanford, CA) | Receptor tyrosine kinase | Sunitinib |
| Ingels et al. (2014) [66] | Renal cell carcinoma | 3 | Orthotopic | Institutional: Stanford (Stanford, CA) | mTOR | MLN0128 (mTOR inhibitor), temsirolimus |
| Sivanand et al. (2012) [32] | Renal Cell Carcinoma | 35 | Orthotopic | Institutional: UT Southwestern (Dallas, TX) | VHL-associated targets | Dovitinib, sirolimus, sunitinib |
| Karam et al. (2011) [67] | Renal cell carcinoma | 4 | Orthotopic and Subcutaneous heterotopic | Institutional: MD Anderson Cancer Center (Houston, TX) | VHL-associated targets | Sunitinib, everolimus |
| Hammers et al. (2010) [68] | Renal cell carcinoma | 1 | Subcutaneous heterotopic | Institutional: Johns Hopkins (Baltimore, MD) | Receptor tyrosine kinase | Sunitinib |